EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease

Jamshid Maddahi, Denis Agostini, Timothy M Bateman, Jeroen J Bax, Rob S B Beanlands, Daniel S Berman, Sharmila Dorbala, Ernest V Garcia, James Feldman, Gary V Heller, Juhani M Knuuti, Pedro Martinez-Clark und 5 weitere

Journal of the American College of Cardiology · 2023-10 · 82 (16) · 1598-1610

DOI: 10.1016/j.jacc.2023.08.016 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American College of Cardiology, 2023-10. Verfasst von Jamshid Maddahi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology (Nuclear Medicine), David Geffen School of Medicine at University of California, Los Angeles, Los An…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Myocardial Perfusion Imaging. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Flurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer. OBJECTIVES: The purpose of this study was to further assess the diagnostic efficacy and safety of flurpiridaz for the detection and evaluation of coronary artery disease (CAD) defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA). METHODS: In this second phase 3 prospective multicenter clinical study, 730 patients with suspected CAD from 48 clinical sites in the United States, Canada, and Europe were enrolled. Patients underwent 1-day rest/stress flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled single photon emission computed tomography (SPECT) before ICA. PET and SPECT images were read by 3 experts blinded to clinical and ICA data. RESULTS: A total of 578 patients (age 63.7 ± 9.5 years) were evaluable; 32.5% were women, 52.3% had body mass index ≥30 kg/m2, and 33.6% had diabetes. Flurpiridaz PET met the efficacy endpoints of the study; its sensitivity and specificity were significantly higher than the prespecified threshold value by 2 of the 3 readers. The sensitivity of flurpiridaz PET was higher than SPECT (80.3% vs 68.7%; P = 0.0003) and its specificity was noninferior to SPECT (63.8% vs 61.7%; P = 0.0004). PET area under the receiver-operating characteristic curves were higher than SPECT in the overall population (0.80 vs 0.68; P < 0.001), women, and obese patients (P < 0.001 for both). Flurpiridaz PET was superior to SPECT (P < 0.001) for perfusion defect size/severity evaluation, image quality, diagnostic certainty, and radiation exposure. Flurpiridaz PET was safe and well tolerated. CONCLUSIONS: This second flurpiridaz PET myocardial perfusion imaging trial shows that flurpiridaz has utility as a new tracer for CAD detection, specifically in women and obese patients. (An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]; NCT03354273).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseMyocardial Perfusion ImagingAgedFemaleHumansMaleMiddle AgedArteriesCoronary AngiographyObesityPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsTomography, Emission-Computed, Single-Photon

Stichwörter der Autor:innen

coronary artery diseaseflurpiridazmyocardial perfusion imagingphase 3 PET trialpositron emission tomography

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Molecular and Medical Pharmacology (Nuclear Medicine), David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Department of Medicine (Cardiology), David Gef…
  • University Hospital Caen, Caen, France.
  • Mid-America Heart, Kansas City, Kansas, USA.
  • University of Leiden, Leiden, the Netherlands.
  • Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Cedars Sinai Medical Center, Los Angeles, California, USA.

Zitieren

APA

Maddahi, J., Agostini, D., Bateman, T. M., Bax, J. J., Beanlands, R. S. B., Berman, D. S., Dorbala, S., Garcia, E. V., Feldman, J., Heller, G. V., Knuuti, J. M., Martinez-Clark, P., Pelletier-Galarneau, M., Shepple, B., Tamaki, N., Tranquart, F., & Udelson, J. E. (2023). Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 82(16), 1598-1610. https://doi.org/10.1016/j.jacc.2023.08.016

Vancouver

Maddahi J, Agostini D, Bateman TM, Bax JJ, Beanlands RSB, Berman DS, et al. Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology. 2023;82(16):1598-1610. doi:10.1016/j.jacc.2023.08.016

BibTeX
@article{Maddahi2023,
  author = {Maddahi, Jamshid and Agostini, Denis and Bateman, Timothy M and Bax, Jeroen J and Beanlands, Rob S B and Berman, Daniel S and Dorbala, Sharmila and Garcia, Ernest V and Feldman, James and Heller, Gary V and Knuuti, Juhani M and Martinez-Clark, Pedro and Pelletier-Galarneau, Matthieu and Shepple, Benjamin and Tamaki, Nagara and Tranquart, Francois and Udelson, James E},
  title = {Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease},
  journal = {Journal of the American College of Cardiology},
  year = {2023},
  volume = {82},
  number = {16},
  pages = {1598--1610},
  doi = {10.1016/j.jacc.2023.08.016}
}
Kostenlos starten →